IJBPAS, July, 2025, 14(7): 3951-3960

ISSN: 2277–4998

International Journal of Biology, Pharmacy and Allied Sciences (IJBPAS)

'A Bridge Between Laboratory and Reader'

www.ijbpas.com

FDA REGULATION FOR MOBILE HEALTH TECHNOLOGIES

YAMUNA V S*, PUNEETH N, PRAKASH S GOUDANAVAR AND ABHISHEK B V

Dept. of Pharmaceutics & Regulatory Affairs, Sri Adichunchanagiri College Pharmacy, ACU, B G Nagar, Karnataka, 571448, India

***Corresponding Author: Ms. Yamuna V S: E Mail: yamunavs5839@gmail.com**

Received 20th March 2024; Revised 24th April 2024; Accepted 16th Aug. 2024; Available online 1st July 2025

https://doi.org/10.31032/IJBPAS/2025/14.7.9231

ABSTRACT

The field of "**mobile health**," **or mHealth**, is anticipated to significantly transform patient care through a range of applications. When utilized for **therapeutic purposes**, mobile applications are increasingly recognized by regulatory agencies as medical devices.

Though they are not obvious, the dynamics of technical advancement and market conception, in particular, are significant forces behind mHealth achievements. To address these matters, the current study looks into **the primary drivers** of the mHealth sector's growth as well as promising directions for innovation that companies should incorporate into their corporate development plans. mHealth products that the FDA has approved so far, based on the innovation of the market and/or goods, and create that new but only a small percentage was accounted for by diversification or new market development. In the case of radical innovation, officers in the pharmaceutical and health device industries are collaborating with newcomers or start-ups with experience in the realm of data and communication skill to shape the current mHealth industry.

Because of the rapid emergence of mobile health (mHealth) apps, the general public and medical experts are confused if goods are evidence-based. The Food and Drug Administration of the United States has little authority over mHealth apps. The accreditation and certification system for laboratory testing under the Clinical Laboratory Improvement Amendment could serve as a model for setting basic quality and safety criteria for mobile health apps. This and that system are interchangeable. When these devices are used to diagnose and treat patients, doctors and patients will have more clout to demand safe and high-quality mHealth apps.

Keywords: Approved, Diagnosis, FDA, mHealth, Therapeutic reasons

INTRODUCTION:

"**mHealth"** or **"mobile health**" is the relatively new idea of applying wireless technologies and mobile devices to medical purposes. "**Medical and public health practice supported by mobile devices such as mobile phones, patient-monitoring devices, personal digital assistants (PDAs), and other wireless devices**" is what is typically referred to as "**mHealth**". The potential for mHealth has increased due to the rising use of smartphones and other mobile devices.

The US Food and Drug Administration (FDA) started to regulate mobile health apps as medical devices as mHealth gained popularity. To support the quickly expanding health sector, the FDA released "Mobile Medical Applications Guidance for Industry and Food and Drug Administration Staff" in 2013. Regardless of whether they have wireless connectivity or not, the FDA refers to handheld **commercial off-the-shelf (COTS)** calculating platforms as "mobile platforms". Tablets, cell phones, and other portable computers are examples of mobile platforms. "**Mobile medical applications**" are well-defined by the FDA as software that does tasks similar to those of medical devices and either improves or converts mobile platforms into regulated medical devices.

mHealth has the ability to completely transform patient care through advancements in the field of medical innovation. There are **two categories** of innovation:

- incremental &
- disruptive.

The gradual transformation of complex and costly products and services into simpler and more reasonably priced ones can be explained by the disruptive innovation theory. Market conditions are altered by disruptive innovation, which inspires others to follow. **Information and communication technology (ICT)** in particular helps to advance a disruptive business model in the medical field. Such technology represents markets, enterprise, and growth, and many businesses must engage in technological innovation-focused operations inside a regulatory framework governed by a variety of laws. Additionally, a company's business plan is essential to its success, and every company aims to position itself in the market through its typical corporate strategies **[1]**.

In terms of **FDA regulation**, the developer or manufacturer, if the item in question is a medical device, must consider multiple levels of analysis, including any FDA approval that would be necessary before lawfully releasing the device onto the market. Depending on the possible health dangers to the public, the first question

determines which of the three FDA classifications—Class I, Class II, or Class 111—the object falls under. These classifications indicate the degree of control required to give the **FDA a reasonable assurance on the efficacy and safety of the product [2]**.

The state of health and medical care might be substantially improved by these technological advancements. However, they also pose special challenges for patients and medical professionals when faced with a virtually infinite array of unproven goods.

In addition to determining the extent of mHealth's existing application in medical practice, the current study aims to identify the important variables propelling a technical route and the creation of the mHealth industry **[3]**.

Objectives:

- To understand the **Overview and the regulation** for mHealth - FDA
- To confer the **public health benefits** and **risks of mHealth** and the **Challenges Facing** by the FDA in regulating this technology.

RESULTS & DISCUSSIONS:

Trends in product and market development:

The second-highest investment has gone into digital therapy, after patient participation in healthcare.

With mHealth, a patient's condition can be visualized and monitored in real-time, and they can contribute to the creation of a knowledge base for product developers.

It was found that the two primary drivers of incremental innovation are the advancement of wireless technology and shrinking. Product downsizing ensures consistency while delivering standard performance at reduced weight, volume, and usefulness. Wireless technologies can alleviate temporal and physical limitations in the diagnosis and treatment of medical diseases. mHealth can set the standard for cutting-edge product development by developing solutions that complement currently available therapies for a range of ailments.

It is accurate to say that data supports the notion of "beyond the pill."

Developing a rapport between physicians and patients, as well as between nurses and patients, is crucial to delivering high-quality medical treatment. Efficient communication between medical professionals and patients is an essential therapeutic undertaking and a basic element of providing healthcare.

Creation of the Industry Network:

The US dominates the world's medical device market in terms of both market share and the number of manufacturers.

The United States will be a universal center for the commercialization of cutting-edge mHealth products supported by its industrial environment to the connection of

technological and market development. Pharmaceutical and medical product R&D provides start-ups and new entrants with assets, capabilities, and credibility by acting as a platform for the development of innovative mHealth products.

Rules Regarding Innovation:

Regulations can help or hurt corporate innovation, depending on the traits of different industries and businesses as well as developments in technology.

It was anticipated that these changes to the regulations would greatly encourage market expansion.

Regulations are expected to stop the reduction as well, particularly in the cutting-edge sector of mHealth. For example, there are over a thousand apps available in the consumer marketplace that can be used to treat depression **[1]**.

To make clear how the Agency plans to exercise its regulatory authority over specific software, such as device software functions and mobile medical apps (MMAs) meant for use on general-purpose computing platforms or mobile platforms, the FDA is providing this guidance. FDA plans to exercise regulatory oversight over certain device software features that fall under the purview of medical devices and whose operation can jeopardize patient safety if the device malfunctions. FDA policy for device software functions and MMAs that satisfy the device definition is outlined in this guidance. Some MMAs and device software functions are subject to FDA regulatory control, while others are exempt from FDA enforcement actions under the Federal Food, Drug, and Cosmetic Act. Additionally, this guideline offers details on a few software features that do not fit the definition of a device and are therefore exempt from relevant FDA regulatory obligations.

The FDA is making its guidelines public to provide software manufacturers with clarity and assurance on this issue.

Following the publication of the final rule, "Medical Devices; Medical Device Classification Regulations To Conform to Medical Software Provisions in the 21st Century Cures Act" (86 FR 20278), this guidance was slightly updated to reflect the revised regulations and to update any content that was impacted by the release of the final guidance, "Clinical Decision Support Software **[3]**.

The **Policy for Device Software Functions and Mobile Medical Applications Guidance**, originally published in 2013 under the title "**Mobile Medical Applications**" (MMA guidance) and revised in 2015, 2019, and 2022, describes the Agency's oversight of device software functions, including mobile medical apps. Software that reduces patient danger in the case of a malfunction or renders conventional medical equipment unfit for use with PCs, mobile devices, or other

platforms is the sole kind of software that is covered by the policy.

The 21st Century Cures Act changed the Federal Food, Drug, and Cosmetic Act (FD&C Act) in Section 520 to allow for modifications to the device definition. The FDA took these modifications into account when they revised their guidelines in 2019. A modification was made to Section 201(h) of the FD&C Act to eliminate specific software functionalities from the device description. Disconnected platforms are those that lack functionalities specified in the device specification

The FDA also explained that software regulations are platform-neutral and function-specific. As such, references to "**mobile application**" in the guidelines and on this page have been replaced with references to "**software function**." In light of this, the FDA changed the guidance's title to "Policy for Device Software Functions and Mobile Medical Applications." The final guidance "Clinical Decision Support Software" was released on September 28, 2022, and the final rule "Medical Devices; Medical Device Classification Regulations to Conform to Medical Software Provisions in the 21st Century Cures Act" (86 FR 20278) were released in 2022. The FDA made a small update to the guidance in 2022 to reflect these developments.

The FDA ensures the safety and efficacy of other medical devices using the same risk-based methodology that it applies to device software functions. This document offers examples of potential FDA regulations for specific device software features. Additionally, the guidelines include examples of software features that:

- are non-devices for medicine.
- are medical devices, but the FDA plans to use its enforcement discretion concerning them, and
- are under FDA supervision and are classified as medical devices.

If software developers have any doubts regarding their program, its level of risk, or whether a premarket application is necessary, we encourage them to email the FDA as soon as possible.

For a wide range of software features that meet the regulatory definition of a "device" but pose little risk to patients and consumers, the FDA will exercise enforcement discretion and will not require manufacturers to file premarket review applications or register and list their software with the FDA. This includes the following device software features:

- course of action;
- or automate easy chores for medical professionals.

Do refer to examples of software functions for which the FDA will use enforcement discretion for a more comprehensive list of

these kinds of device software capabilities that are not under FDA supervision **[4]**.

The FDA's Mobile Medical App Regulation:

The United States Food and Drug Administration (FDA) is the government agency responsible for overseeing and regulating medical devices, including mobile medical applications. Since releasing its "FDA Policy for the Regulation of Computer Products" in 1989, the FDA has been closely monitoring the usage of software products in conjunction with medical devices. Over the following 20 years, the government made numerous changes to rules and regulations to keep up with the rising use of software in the healthcare industry.

The FDA has acknowledged the growing significance of mobile platform software in the delivery of healthcare services. A draft set of guidelines was released by the government in July 2011 to help software developers and administrative staff understand the regulatory landscape around mobile medical apps.

After receiving more than 130 comments on the draft guideline document, the FDA published a final guideline paper with comprehensive regulatory guidelines for mobile medical apps in September 2013.

Mobile Medical App Types Covered by FDA Regulations:

Rather than trying to regulate every mobile medical app, the FDA will focus its efforts on a select few that are most likely to put people in danger. The following types of mobile health applications are governed by agency regulations:

1. Serve as a wired or wireless extension to an established medical equipment, enabling it to be controlled or to show, store, analyze, or communicate data particular to a patient that the device creates.

2. Transform a mobile platform, such as a mobile phone or tablet computer, into a regulated health device with features that are similar to those of other regulated medical devices by adding attachments, display panels, or sensors.

3. Perform a patient-specific analysis or provide therapeutic suggestions or a patient-specific diagnosis.

FDA Rules That Apply to Medical Apps on Mobile Devices:

The FDA's guideline paper includes an outline of the regulations that are applicable to mobile medical apps as well as all medical devices in Appendix E.

Particular prerequisites consist of:

- **Medical Device Listing and Establishment Registration-** The company's registration and the furnishing of an exhaustive inventory of all medical equipment sold: It is necessary for producers of

medical devices—including those who develop mobile applications—to register with the FDA. A manufacturer's registration and device listing need to be updated annually.

- **Submission for permission or approval before to market-** Developers of mobile medical applications are required to prepare and submit a premarket submission (510(k)) application to the FDA by the risk categorization that applies to their app. The guidance document includes examples of certain medical equipment along with their corresponding risk class in Appendix D.
- **Rules governing the quality system-** According to the FDA's quality system (QS) guideline, mobile medical app developers must have procedures and systems in place for designing, manufacturing, and distributing safe and efficient products. Additionally, the relevant mobile platform must validate and approve the work that developers of medical mobile apps perform.
- **Labelling of products -** The FDA's regulations regarding device labelling must be followed by all medical devices, including mobile medical apps.
- **Notifying of adverse events-** Ultimately, mobile medical apps are subjected to the FDA's medical device reporting requirement. App creators are required to investigate any situation in which a mobile medical app is believed to have caused or contributed to a significant injury or death, or in which an app malfunctioned and placed a patient in danger of harm or death. App developers also have to submit written reports to the FDA for each of these incidents.

Additional Relevant FDA Rules:

Mobile medical apps may be subject to device or public-related regulations, such as those set forth by the FDA for wireless medical devices and addressing problems like radio frequency interference. Medical devices meant for home use are also subject to FDA regulation, which takes user-friendliness into consideration. Depending on its intended purpose and whether it will be integrated with other medical devices, a mobile medical app may have different requirements **[5]**.

Challenges:

The FDA released recommendations on mobile medical applications in September 2013, which sparked debate. A different

group of 140 stakeholders, led by Athena Health, requested a postponement until January 2014, when a more comprehensive health IT platform would be accessible. To ensure clarity, the mHealth Regulatory Coalition wanted it released to the public as soon as feasible.

The mHealth Regulatory Coalition applauded the release of the guidelines, but industry observers pointed out that the FDA has not explicitly declared which apps are subject to regulation and that the guidance's ambiguous wording may be interpreted differently.

The FDA is anticipated to provide a comprehensive framework for health IT regulation by January 2014, emphasizing patient safety, efficacy, and innovation. Clinical decision support application software was not included in the agency's final recommendations from September; this is another area where the framework will be helpful in creating guidelines. The goal is to avoid unnecessary restrictions and simplify the mHealth application process.

Patient safety, innovation, and efficient regulation were prioritized by the FDASIA panel in its final framework recommendations. Avoiding needless regulation is the last requirement since it would be confusing and postpone the launching of mHealth apps. With the help of the January framework, the FDA and other agencies will likely be able to develop regulations for clinical decision support application software and other material that the agency left out of its final guidelines **[6]**. Using a theme analysis approach based on predetermined criteria and data gathering, the study examined 32 significant publications. This study highlighted nine potential roadblocks to the development of safe mobile health applications. Developing safe mobile health applications is hampered, among other things, by a lack of security policies and guidelines (20/32, 63%); inexperience and ignorance among developers (18/32, 56%); lack of involvement from stakeholders (19%); and disregard or indifference on the part of developers towards the security of mobile health apps (5/32, 16%),Funding issues (4/32, 13%), project limitations throughout development (4/32, 13%), security testing deficiencies (4/32, 13%), developer disinterest and disregard for ethics (3/32, 9%), and a shortage of security professionals during development (2/32, 6%). in order to develop a mobile health app that is secure. Based on analysis, we have presented a conceptual framework that highlights the correlation between the identified challenges **[7]**.

CONCLUSION:

Mobile medical applications are increasingly being used to offer healthcare services, but developers may be unsure if their solutions are subject to the FDA's

medical device regulation. The FDAs recently issued mobile medical application guideline paper offers specific details on how the agency intends to regulate these goods. It is not, however, a substitute for a complete understanding of the regulations and processes governing mobile medical apps.

While security may not always be the first priority for organizations developing mHealth apps, we believe our study will assist them in identifying gaps and improving their security protocols. In a similar spirit, developers may find it challenging to create apps for mobile health. User security must be provided by these apps. Our study is the first step in providing insights into the development of safe mobile health apps. As a useful guide, we provide practitioners with a conceptual framework to improve the security of their mHealth app development.

ACKNOWLEDGEMENT:

The author wants to acknowledge the management of Sri Adichunchanagiri College of Pharmacy for their valuable support.

CONFLICT OF INTEREST:

The authors declared that there is no conflict of interest

REFERENCE:

[1] International Journal of Medical Informatics [Internet]. [cited 2023 Dec 6]. Available from: https://www.sciencedirect.com/journal/international-journal-of-medical-informatics/vol/124/suppl/C

[2] Larson RS. A path to better-quality mhealth apps [Internet]. U.S. National Library of Medicine; 2018 [cited 2023 Dec 6]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090170/

[3] Center for Devices and Radiological Health. Policy for device software functions and mobile medical applications [Internet]. FDA; [cited 2023 Dec 6]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-device-software-functions-and-mobile-medical-applications

[4] [Internet]. [cited 2023 Dec 6]. Available from: https://code-authorities.ul.com/wp-content/uploads/sites/40/2015/02/UL_WP_Final_The-US-FDAs-Regulation-and-Oversight-of-Mobile-Medical-Applications_v6_HR.pdf

[5] [Internet]. [cited 2023 Dec 6]. Available from: https://www.healthaffairs.org/do/10.1377/hpb20131205.399529

[6] Gaziel-Yablowitz, M., & Schwartz, D.G. (2018). A Review and Assessment Framework for Mobile-

Based Emergency Intervention Apps. ACM Computing Surveys (CSUR), 51, 1 - 32.

[7] MA; AB. Challenges with developing Secure Mobile Health Applications: Systematic Review [Internet]. U.S. National Library of Medicine; [cited 2023 Dec 6]. Available from: https://pubmed.ncbi.nlm.nih.gov/34152277/